Abstract: The present invention provides a speed measurement method and apparatus using a plurality of cameras. The speed measurement method includes: S1: calibrating positions of the respective cameras in a camera group, which are on a mobile platform at fixed relative positions; S2: obtaining a sequence of synchronized images from the respective cameras in the camera group, and recording time stamps thereof; and S3: performing a registration on the images captured by the respective cameras in the camera group and, if a registration result of two of the images is greater than a first threshold, calculating a position transformation matrix for the two images, and then calculating a position transformation matrix for the mobile platform based on the positional relationships between the cameras that captured the two images, and finally calculating a speed information of the mobile platform based on the position transformation matrix and an interval between times when the two images were captured.

Abstract: The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule hCAR activator in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) by preferential induction of CYP2B6 over CYP3A4 and promoting the formation of therapeutically active CPA metabolite 4-OH-CPA.

Abstract: The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule hCAR activator in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) by preferential induction of CYP2B6 over CYP3A4 and promoting the formation of therapeutically active CPA metabolite 4-OH-CPA.